Abstract
A simple, sensitive, selective, rapid, reproducible and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the identification and quantification of paroxetine (PAX) in human plasma,. Chromatographic separation was performed on XTerra RP18 (5 μm, 150 mm × 4.6 mm i.d.) column with mobile phase composed of 10 mM ammonium acetate containing 0.2% formic acid: methanol (30:70, v/v) at flow rate of 0.9 mL min-1. PAX and CZP were detected with proton adducts at m/z (amu) 330.1 192.1 and 327.2 270.1, in multiple reaction monitoring (MRM) positive mode. The method was validated over the concentration range of 0.05 - 30 ng mL-1. The lower limit of quantification (LLOQ) was 0.05 ng mL-1. The inter-run and intra-run precision was within 2.1-11.8% and 2.2-5.8%, respectively
Publisher
Trans Tech Publications, Ltd.
Reference9 articles.
1. Foglia JP, Sorisio D, Kirshner M, Pollock BG. Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl 1997; 693 (1): 147-51.
2. Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev 2001; 7 (1): 25-47.
3. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51(3): 288-95.
4. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992; 33 (5): 521-3.
5. Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), May (2001).